Update on Actos Bladder Cancer Litigation

Actos multidistrict litigation over claims it causes bladder cancer is being consolidated in the U.S. Federal Court for the Western District of Louisiana.

 

Next Status Conference in Actos Litigation Scheduled for November 15th.

 

The ever growing Actos litigation in a Louisiana federal court is set for its next status conference before Judge Rebecca Doherty on November 15, 2012. All of the federal lawsuits against Actos maker Takeda have been consolidated in In re: Actos Product Liability Litigation, MDL No. 2299 9. (Click here for case schedule). The U.S. Judicial Panel on Multidistrict Litigation was formed in December 2011. This MDL process was first created by Congress in the 1960s and is responsible for determining when judicial efficiency would best be served, when cases sharing a common set of facts and are filed in multiple districts, by consolidating them into a single district for pre-trial proceedings. This is done to increase the efficiency of the federal courts and to increase settlement opportunities between the various sides.

 

Slater Slater Schulman Brought One of the First Actos Cases.

 

Actos bladder cancer lawsuit cases deal with allegations that Takeda concealed the risks of Actos causing bladder cancer, and further failed to give Actos users of adequate warnings of the potentially lethal side effects. The FDA approved Actos in 2009 to treat Type II diabetes, however several studies, the FDA, and many countries in Europe, have raised alarms that Actos is dangerous due to the increased risk of bladder cancer. In August 2011, Slater Slater Schulman brought one of the first Actos bladder cancer lawsuits in the country. (Click here for complete story).

 

Growing Body of Research Linking Actos to Bladder Cancer

 

France and Germany pulled Actos off the market in June 2011 over concerns with increased bladder cancer risks. Later that same month the FDA issued a caution to patients taking Actos for more than one year that they may have an increased risk of bladder cancer. A 2011 study released using data from Kaiser Permanente Northern California showed that Actos patients taking the drug for more than 12 months faced an approximately 40 percent increased risk of developing bladder cancer.

 

The studies linking Actos to bladder cancer have continued to mount. The British Medical Journal released a study in May of 2012 that concluded Actos, taken over two years, can double the risk of bladder cancer. Another study released in July of 2012 by the Canadian Medical Association showed a 22 percent increased risk of bladder cancer in Actos patients. The FDA is currently conducting its own study investigating links between Actos and bladder cancer.

 

With the steady stream of studies linking Actos to bladder cancer and the questions about Takeda’s knowledge and disclosure of those risks, the litigation against Takeda is likely to continue to grow. If you or your loved one has taken Actos and subsequently developed bladder cancer time may be running our to protect your legal rights, contact an Actos attorney today. Experienced Actos attorneys such as those at Slater Slater Schulman LLP will investigate your legal rights before it is too late.  If you or someone you love have developed bladder cancer after using Actos, you should contact Slater Slater Schulman LLP for a free consultation by filling out the form on this page or by calling us at (800) 251-6990.

 

Tagged with:
 

1 Response » to “Update on Actos Bladder Cancer Litigation”

  1. I don’t think I have a case for you,I only took Actos for a year back in 2000 and had no ill effects.I want instead,to convey my outrage at Eli Lilly Actos/Zyprexa duplicity fraud!

    Actos is produced by Takeda Industries and co-marketed by Eli Lilly.
    Eli Lilly Zyprexa can *cause* diabetes.
    I took Zyprexa olanzapine a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.
    Eli Lilly’s #1 cash cow Zyprexa drug sale $67 billion dollars so far,has a ten times greater risk of causing type 2 diabetes over the non-user of Zyprexa. So,here we have a conflict of interest that this same company Eli Lilly also is a big profiteer of diabetes treatment.
    (Actos works as an insulin *sensitizer*)
    Sooooo,Eli Lilly pushes a drug (Zyprexa) that can cause diabetes…. then turn around sell you the drugs (Actos) to treat the diabetes that in turn can cause cancer!
    What a terrible conflict of interest!
    — Daniel Haszard

Leave a Reply

 

Anti-Spam Protection by WP-SpamFree




Follow Us on:

Contact Us

Privacy Policy

Please click here to view our privacy policy.